Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Systematic Review: Charged-Particle Radiation Therapy for Cancer
Annals of Internal Medicine, 10/20/09
Terasawa T et al. – Currently, 7 centers in the United States have facilities for particle (proton)–beam irradiation, and at least 4 are under construction, each costing between $100 and $225 million. In 243 eligible articles, charged–particle radiation therapy was used alone or in combination with other interventions for common (for example, lung, prostate, or breast) or uncommon (for example, skull–base tumors or uveal melanomas) types of cancer. Of 243 articles, 185 were single–group retrospective studies. Eight randomized and 9 nonrandomized clinical trials compared treatments with or without charged particles. This review found that published evidence about the benefits and harms of charged–particle radiation therapy was derived mostly from small, single–group, retrospective studies. Of the 17 studies that compared treatments with or without charged particles, none reported statistically significant or important differences in overall or cancer–specific survival or in total serious adverse events.
Related Articles
Quality Care Means Provider Status for Clinical Radiation Oncology Physicists
Imaging Economics, 10/01/09
Relevance Score: 69%
In utero exposure to therapeutic radiation for Hodgkin lymphoma
Canadian Family Physician, 10/14/09
Relevance Score: 67%
Prostate cancer: Quality of life after radiation and androgen deprivation
NCP Urology, 10/13/09
Relevance Score: 66%
Ovarian ablation by radiation therapy: Is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients?
The Breast, 10/08/09
Relevance Score: 66%
Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells
Urology, 10/06/09
Relevance Score: 66%
Today in Radiotherapy (XRT)...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors
Neuroendocrinology, 12/09/09
Radiosynthesis of N-[4-(4-fluorobenzyl)piperidin-1-yl]-N-(2-[11C]oxo-1,3-dihydrobenzimidazol-5-yl)oxamide, a NR2B-selective NMDA receptor antagonist
Journal of Labelled Compounds and Radiopharmaceuticals, 12/08/09
Effects of functional electrical stimulation on dysphagia caused by radiation therapy in patients with nasopharyngeal carcinoma
Supportive Care in Cancer, 12/08/09
Sponsor
Article Search
Sponsor


See Latest Articles


